The subcutaneous colorectal cancer CT26 model was used to test the efficacy of IOA-244 alone (30 mg/kg twice daily, orally) and in combination with anti-PD-L1 (10 mg/kg once every other day, i.p.), which was also included as a monotherapy control arm (Supplementary Fig. S4A). This evidence concerns the gene CD274 and colorectal cancer.